Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 7, 2008, Pages 2670-2678

  Elkind Hirsch, Karen ^a,c   Marrioneaux, Ory ^b   Bhushan, Madhu ^b   Vernor, Denise ^b   Bhushan, Rajat ^b  

^a WOMAN S HOSPITAL   (United States)

^b Metabolic Center of Louisiana Research Foundation   (United States)

^c Woman's Health Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANDROGEN; C REACTIVE PROTEIN; CHOLESTEROL; EXENDIN 4; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL CRAMP; ABDOMINAL FAT; ACNE; ADULT; ANTHROPOMETRY; ARTICLE; BLOATING; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DYSFUNCTIONAL MENSTRUAL BLEEDING; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HEARTBURN; HOT FLUSH; HUMAN; INDIGESTION; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MENSTRUAL CRAMP; MENSTRUAL CYCLE; MENSTRUATION; MENSTRUATION DISORDER; MIGRAINE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PAIN; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 47549095688     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0115     Document Type: Article

References (39)

1. Rotterdam Workgroup. 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19-25
2. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774-800
3. Dunaif A, Finegood DT 1996 1996 β-Cell dysfunction independent of obesity and glucose tolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:942-947
4. Ehrmann DA, Breda E, Corcoran MC, Cavaghan MK, Imperial J, Toffolo G, Cobelli C, Polonsky KS 2004 Impaired β-cell compensation to dexamethasone-induced hypoglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab 287:E241-E246
5. Norman RJ, Masters SC, Hague W, Beng C, Pannall P, Wang JX 1995 Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertil Steril 63:329-335
6. Diamanti-Kandarakis E, Papavassiliou AG 2006 Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 12:324-334
7. Zaadstra BM, Slidell JC, Van Noord PA, te Velde ER, Abeam JD, Vrieswijk B, Karbaat J 1993 Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. Br Med J 306:484-487
8. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE 2001 Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 286:2421-2426
9. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE 2007 Glucose intolerance in polycystic ovary syndrome: a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 92:4546-4556
10. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ 1995 Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 10:2705-2712
11. De Leo V, la Marca A, Petraglia F 2003 Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24:633-667
12. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R 1996 The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:3299-3306
13. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN; PCOS/Troglitazone Study Group 2001 Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86:1626-1632
14. Velasquez EM, Mendoza, Harner T, Sosa F, Glueck CJ 1994 Metformin therapy in polycystic ovarian syndrome reduces hyperinsulinaemia insulin resistance, hyperandrogenaemia and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism 43:647-654
15. Lord J, Wilkin T 2004 Metformin in polycystic ovary syndrome. Curr Opin Obstet Gynecol 16:481-486
16. Drucker DJ 1998 Glucagon-like peptides. Diabetes 47:159-169
17. Nielsen LL, Young AA, Parkes DG 2004 Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117:77-88
18. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA 2005 Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90:5991-5997
19. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD 2003 Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377
20. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100
21. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091
22. Elkind-Hirsch K, Darensbourg C, Ogden B, Ogden L, Hindelang P 2007 Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception 76:348-356
23. Mathur, RS, Moody LO, Landgrebbe S, Williamson HO 1981 Plasma androgens and sex hormone binding globulin in the evaluation of hirsute patients. Fertil Steril 35:29-37
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
25. Matsuda M, DeFronzo R 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462-1470
26. Seltzer HS, Allen EW, Herron Jr AL, Brennan MT 1967 Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 46:323-335
27. Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H 1976 Glucose tolerance and insulin release, a mathematical approach. I. Assay of the β-cell response after oral glucose loading. Diabetes 25:241-244
28. Hanson RL, Pratley RE, Bogardus C, Venkat Narayan KM, Roumain JML, Imperatore G, Fagot-Campagna A, Pettitt DJ, Bennett PH, Knowler WC 2000 Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151:190-198
29. Sönmez AS, Yaar L, Savan K, Koç S, Özcan J, Toklar A, Yazcolu F, Akgün A, Sut N 2005 The effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome Hum. Reprod 20:175-179
30. Bruno RV, de Avila MA, Neves FB, Nardi AE, Crespo CM, Sobrinho AT 2007 Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference. Fertil Steril 88:510-512
31. King AB, Wolfe G, Healy S 2006 Clinical observations of exenatide treatment. Diabetes Care 29:1984
32. Lord J, Thomas R, Fox B, Acharya U, Wilkin T 2006 The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome: a randomised, double-blind, placebo-controlled trial. Brit J Ob Gynecol 113:817-824
33. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Déchaud H, Pugeat M 1995 Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 80:2057-2062
34. DeUgarte CM, Bartolucci AA, Azziz R 2005 Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83:1454-1460
35. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS 1997 Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:524-530
36. Spranger J, Möhlig M, Wegewitz U, Ristow M, Pfeiffer AFH, Schill T, Schlosser HW, Brabant G, Schöfl C 2004 Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 61:738-746
37. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D 2006 Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21:1426-1431
38. Moran LJ, Noakes M, Clifton PM, Wittert GA, Belobrajdic DP, Norman RJ 2007 C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome J Clin Endocrinol Metab 92:2944-2951
39. Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G, Schofl C 2004 The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150:525-532